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Abstract
Mice bearing a ‘‘humanized’’ immune system are valuable tools to experimentally manipulate human cells in vivo and
facilitate disease models not normally possible in laboratory animals. Here we describe a form of GVHD that develops in
NOD/SCID mice reconstituted with human fetal bone marrow, liver and thymus (NS BLT mice). The skin, lungs,
gastrointestinal tract and parotid glands are affected with progressive inflammation and sclerosis. Although all mice showed
involvement of at least one organ site, the incidence of overt clinical disease was approximately 35% by 22 weeks after
reconstitution. The use of hosts lacking the IL2 common gamma chain (NOD/SCID/cc
2/2) delayed the onset of disease, but
ultimately did not affect incidence. Genetic analysis revealed that particular donor HLA class I alleles influenced the risk for
the development of GVHD. At a cellular level, GVHD is associated with the infiltration of human CD4+ T cells into the skin
and a shift towards Th1 cytokine production. GVHD also induced a mixed M1/M2 polarization phenotype in a dermal murine
CD11b+, MHC class II+ macrophage population. The presence of xenogenic GVHD in BLT mice both presents a major
obstacle in the use of humanized mice and an opportunity to conduct preclinical studies on GVHD in a humanized model.
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Introduction
Humanized mice have proven to be a valuable model that
enables both the study of human-specific diseases such as HIV and
the experimental manipulation of human cells in vivo [1,2,3]. In
particular, the nonobese diabetic/severe combined immunodefi-
ciency (NOD/SCID, hereafter NS) model, whereby immunode-
ficient NS or NOD Rag2
2/2 mouse hosts are reconstituted with
human CD34+ cells, has been widely used and informative [2].
Advances on this model include the use of NOD/SCID/cc
2/2
(hereafter, NSG) hosts where deficiency for the IL2 receptor
gamma chain promotes improved engraftment [1,4,5]. Further-
more, surgical transplantation of human fetal liver and thymus
alongside the engraftment of human bone marrow (hereafter BLT
for bone marrow, liver and thymus) facilitates robust T cell and
humoral immune responses by allowing T cells to be educated on
syngenic human thymic tissue [1,6,7].
Here we report a major obstacle in the use of humanized mice.
NS BLT and NSG BLT mice develop a spontaneous xenogenic
graft versus host disease (GVHD) characterized by lymphocytic
infiltration and sclerosis of the skin, GI tract, parotids and lungs,
culminating in death. All NS BLT and NSG BLT mice examined
displayed disease in at least one organ system. In considering
humanized mouse models, GVHD both reduces the number of
usable mice in a cohort and additionally complicates the results of
disease models conducted in humanized mice by overlaying a
second set of pathologies. Thus, as the technology of humanized
mice as a platform to study T and B cells advances and donor
cellular function improves, these advances will be met with
commensurate increases in the incidence of GVHD. Along with
these challenges, the occurrence of GVHD simultaneously
presents an opportunity for the experimental study of GVHD
and similar fibrotic autoimmune disorders, such as slceroderma, in
a humanized system.
Materials and Methods
Generation and Housing of the BLT model
BLT mice were prepared as previously described [1]. Briefly,
NOD/SCID or NOD/SCID/cc
2/2 mice 6–8 weeks old were
sublethally irradiated with 2Gy, anesthetized, and 1mm fragments
of human fetal thymus and liver (Advanced Bioscience Resources)
were implanted under the kidney capsule, either unilaterally or
bilaterally. Additionally, CD34+ cells were isolated from fetal liver
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5 cells were
injected intravenously within 6 hours after surgery. All surgery
was performed under anesthesia and all efforts were made to
alleviate any suffering associated with these procedures. All mice
were subsequently housed in microisolator cages in a specific
pathogen-free facility in accordance with Institutional Animal
Care and Research Committee-approved protocols at Massachu-
setts General Hospital. The Massachusetts General Hospital
Institutional Animal Care and Research Committee specially
approved this study.
Isolation of Skin Infiltrating CD4+ T cells and
macrophages, and splenic T-cells
This was performed as previously described [8]. Approximately
10 cm
2 pieces of back skin were shaved, washed with PBS, and
digested for 1 hour with 0.27% collagenase type XI (Sigma) and
1 mg/10mL of hyularonidase type IV (Sigma) in RPMI medium.
The resulting cell suspension was filtered over a 70 mm strainer,
and stained with the listed antibodies for FACS on a FACS Aria
(BD Biosciences, Franklin Lakes, NJ). All antibodies were from BD
biosciences except for anti-human CD3 (Biolegend, San Diego,
CA). RNA was isolated from sorted macrophages using qiazol
(Quiagen). T cells were restimulated with PMA/ionomycin.
Alternatively, splenic CD4+ T cells were isolated using magnetic
bead purification with anti-human CD4 (Miltenyi, Germany).
Isolated CD4+ T cells were resimulated with PMA/ionomycin.
Explant Cultures, ELISA, and autoantibody screen
Back skin from shaved GVHD and control mice was trimmed to
1c m
2 sizes and cultured overnight in RPMI-1640 with 10%FCS
and antibiotics. For ELISA analysis, supernatants from either skin
explants or T cell cultures were analyzed using Legend-Max kits
from Biolegend for IL10, IFNc, or IL4 or a kit from eBioscience
for IL17. An autoantibody screen was conducted by the Brigham
and Women’s Hospital clinical laboratories using indirect immu-
nofluorescence to evaluate the serum reactivity to the HEP2 cell
line [9]. The HEP2 cell line was maintained internally by the
Brigham and Women’s Hospital clinical laboratories. Additionally,
a clinical EIA was run to test for anti-Scl70 antibodies.
Quantitative realtime PCR
RNA was isolated from the indicated cells or tissues by qiazol
(Qiagen, Germany) and cDNA synthesized using a kit from
Applied Biosciences. Realtime PCR was performed using the
Brilliant II SYBR Green Master Mix (Stratagene, Santa Clara,
CA) on a Mx3005P qPCR system (Stratagene).
Results
Gross and Histologic Characterization of GVHD in
humanized BLT mice
GVHD in NOD SCID (NS) and NOD SCID cc
2/2 (NSG)
BLT mice developed via a stereotypic order of events (Figure 1).
First mice manifest blepharitis or conjunctivitis along with ruffled
fur. Second, alopecia develops on either the face or at the site of
the surgical scar from the implantation procedure (Figure 1A) and
subsequently spreads to involve the entire body. Lastly, many
affected mice succumb to the disease. Blepharitis develops starting
at 12 weeks post reconstitution and mice succumb to disease
starting at 15 weeks after reconstitution (Figure 1B). Histologically,
skin involvement is characterized by a lymphocytic infiltrate of the
epidermis, hair follicle, and dermal/subcutaneous junction with
corresponding dropout of hair follicles, loss of subcutenaous fat,
epidermal hyperplasia and hyalinization of dermal collagen,
features similar to those observed in human GVHD or scleroder-
ma (Figure 1C, Information S1). Occasional ulceration of the
epidermis was also observed (Information S1). Blinded scoring of
skin histology from BLT GVHD and donor-matched healthy
control mice confirmed substantial increases in inflammation,
epidermal hyperplasia, fibrosis and subcutaneous lipoatrophy
scores in clinically affected animals (Figure 1D).
Just as GVHD is a systemic process in humans, several organs
other than the skin are affected in BLT mice. The parotid glands
were involved with a lymphocytic infiltrate and sclerosis
surrounding central ducts (Figure 1D, Information S1). Colitis
characterized by a lamina propria infiltrate was also present
(Information S1). Notably, the lungs of all mice, even those
without any overt clinical disease, all had a dense lymphocytic and
macrophage-rich infiltrate sheathing the bronchi and pulmonary
arteries, resulting in destruction and engulfment of the smooth
muscle in the adventitia (Figure 1E, Information S1). No
significant thryoiditis, pancreatitis or esophagitis was detected.
To evaluate for a humoral component of disease, the serum of
NS BLT mice with GVHD was screened by indirect immunoflu-
orescence for anti-nuclear antibodies (data not shown). No
reactivity to Hep2 cells was detected. Anti-Scl70 antibodies are
found in patients in a subset of patients with diffuse scleroderma as
well as a fully murine model of chronic GVHD [10]. ELISA
screening for serum anti-scl70 antibodies was negative in NS
GVHD mice.
The Contribution of Donor HLA class I alleles to the
Development of GVHD
Specific donor HLA class I alleles have been identified as strong
genetic modifiers of the incidence and manifestations of human
GVHD [11,12]. To determine the effects of HLA class I, 50 donor
cohorts comprising approximately 1700 mice were typed for
donor HLA class I alleles and data regarding the incidence of
GVHD was collected (Figure 2A-C, Information S1). Contingency
table analysis was used to calculate the relative risk of each specific
HLA allele present in at least 3 independent cohorts. After chi-
squared analysis and correction for multiple comparisons the
following HLA Class I alleles showed a significant increase in the
relative risk of GVHD: A1101, A2402, A3303, A201, B1302,
B3502, C602, and C401. HLA A3201, B801, and B1401 showed a
significant protective effect.
The Effects of cc , HIV infection and lymphoid
reconstitution on GVHD
In an attempt to identify hosts that would avoid the
development of GVHD during the production of humanized
mouse cohorts, the kinetics of GVHD was compared in NOD
SCID (NS) and NOD SCID cc
2/2 (NSG) hosts. cc is a shared
component of the receptor for IL-2, IL-4, IL-9, IL-15, and IL-21,
and NSG mice have been used as humanized mouse hosts as they
display improved engraftment of human hematopoietic stem cells
[13,14,15,16]. NSG hosts displayed a significant delay in the onset
of GVHD of approximately 6 weeks. However the cumulative
incidence of disease by 35 weeks after reconstitution was the same
in both groups at about 35% (Figure 2D). Comparisons of disease
in NS and NSG mice at the histologic and gene expression level
did not reveal any significant differences (data not shown).
As a major use for humanized mice is to serve as an
experimental platform for studies of HIV infection, the effects of
HIV on GVHD incidence were studied (Figure 2E). HIV infection
both promoted an approximately 8 week earlier disease onset and
GVHD in BLT Humanized Mice
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uninfected, donor-matched controls. However, at the cohort size
available (n=34 uninfected, n=40 HIV infected) these effects
failed to reach statistical significance (P=.107 by a Mantel-Cox
test), perhaps due to the crossing hazard functions undercutting
the power of analysis. This trend is consistent with a model
whereby early HIV infection has an innate immune costimulatory
function that promotes disease, and later HIV-mediated CD4+
depletion ultimately lowers the cumulative incidence.
Figure 1. Clinical and Pathologic Description of GVHD in BLT mice. (A) Gross findings in BLT GVHD, demonstrating facial and trunk alopecia
and blepharitis. (B) Kinetics of disease progression in NOD SCID cc
2/2 mice. Initial n=389. Subjects enrolled in specific experimental protocols were
censored at the time of enrollment. (C–E) Representative histologic images of the indicated organs. 6 mice with GVHD and 6 healthy controls were
analyzed. Original magnification, 100X. (F) Pathologic scoring of the skin, demonstrating that epidermal hyperplasia, inflammation, fibrosis and
subcutaneous fat loss all correlate with the clinical manifestations of GVHD. ‘‘*’’ indicates p,.02 by a two-tailed Mann Whitney test. n=5 mice per
group.
doi:10.1371/journal.pone.0044664.g001
GVHD in BLT Humanized Mice
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as measured as percentage CD3+ cells present in a peripheral
blood sample 14 weeks after reconstitution and the rate of GVHD
was compared between different donor cohorts (Figure 2F). As
expected, there was a significant correlation between the degree of
reconstitution and GVHD incidence, however it is notable that
even cohorts with low to undetectable levels of lymphoid
reconstitution developed GVHD at a detectable rate. This suggests
that, as opposed to general T cell reconstitution, the presence of
certain pathogenic T cell clonotypes that may be present below the
limit of detection in peripheral blood and expand at the sites of
pathology is the critical factor in the development of GVHD.
Molecular Characterization of GVHD
To explore the mechanisms of disease at the molecular and
cellular levels, the cytokines produced by skin explants from
affected and donor-matched controls were measured. Develop-
ment of GVHD correlated with an approximately 3-fold increase
in human IFNc production (Figure 3A). Human IL4, IL17, IL21,
IL23 and IL10 were all below the limit of detection in the same
cultures (data not shown). Additionally, RNA was prepared from
the skin of affected mice and controls (Figure 3B). One strength of
the BLT GVHD system is that, by choosing human or murine
specific primers, the expression of genes in the human immune
infiltrate can be distinguished from that in the murine stroma or
innate immune cells. A signal for a human housekeeping gene
HPRT was absent in healthy BLT mice, demonstrating that
human immune infiltrates are largely absent from the skin of
healthy mice. This also precludes a relative comparison of
expression levels between human genes in GVHD and healthy
control mice. GVHD mice displayed robust expression of human
IFNc, and the pro-fibrotic mediators human IL13 and human
CCL2 (Figure 3B) [8]. No murine IFNc could be detected, arguing
that human infiltrating immune cells are the sole source of IFNc in
the skin (data not shown). Development of GVHD induced
increases in the expression of the inflammatory markers, murine
Cox2 and Nos2 (Figure 3C). We have previously characterized that
Figure 2. The influence of specific graft HLA class I alleles, host cc deficiency, HIV infection, and degree of reconstitution on the
development of GVHD. (A–C) HLA class I data and the incidence of GVHD was recorded for each of over 1800 mice comprising 46 cohorts. Only
those HLA class I alleles represented in at least 3 independent cohorts were included in the analysis. The relative risk for each HLA allele is displayed.
Error bars represent the 95% confidence interval. Significance was determined by the chi-squared test with the Bonferroni correction applied for
multiple comparisons. (D) The kinetics of GVHD onset were determined in NOD SCID and NOD SCID cc
2/2 hosts. P,.05 by a Gehan-Wilcoxon test. For
NOS SCID n=61, for the NOD SCID cc
2/2 group n=343. Error bars represent the 95% confidence interval. (E) The effect of HIV infection on GVHD
incidence in NSG hosts. p=ns by a Gehan-Wilcoxon test. n uninfected=34, n HIV infected=40. Error bars represent the 95% confidence interval. (F)
The total percent of human CD3+ T cells present in the peripheral blood of humanized BLT mice at 14 weeks after reconstitution was plotted. Each
dot represents the average percentage of CD3+ cells and the rate of GVHD present in a given cohort of mice reconstituted with a single donor. The
line of best fit is plotted. The slope is. 008712 (95% confidence interval. 001348 to. 01608, P value .0212).
doi:10.1371/journal.pone.0044664.g002
GVHD in BLT Humanized Mice
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induction and severity of fibrotic skin diseases such as scleroderma
[8]. Consistent with the fibrotic skin disease seen in the BLT
GVHD mice and the above expression of IL13, expression of the
IL13 target gene, murine Sprr2a, was increased (Figure 3C) [17].
Additionally, we have previously observed that expression of
IL13Ra1 correlated with an IL13 response signature in both a
mouse model of sclerodermatous GVHD and in human sclero-
derma [8]. Consistent with the increase in Sprr2a levels, expression
of murine IL13Ra1 was also increased.
Characterization of T cell and macrophage populations in
GVHD
To directly examine the composition of the inflammatory
infiltrate in the skin, skin was processed by collagenase digestion,
and the resulting cell suspension was analyzed by FACS. Human
CD4+ T cells were present in mice with clinical GVHD, but only
small numbers were present in unaffected HLA-matched controls
(Figure 3D). Human CD19+ B cells, CD8+ T cells, CD11c
positive dendritic cells were not present at significant levels (data
not shown). Skin infiltrating CD4+ T cells were sorted and
restimulated in vitro and their cytokine secretion profile analyzed
by ELISA (Figure 3E). Development of GVHD was associated
with a substantial shift towards IFNc production and away from
IL17 production. IL4 secretion was below the limit of detection. A
similar skewing towards increased IFNc production was seen in
CD4+ cells isolated from the spleen (Figure 3F). IL10 was
detectable in both the restimulated skin and spleen cultures, but
was unchanged in GVHD mice (Figure 3E and Information S1).
IL21 was not produced at detectable levels in the same set of
supernatants (data not shown). Taken together, this analysis
supports a model whereby skewing CD4+ T cells towards Th1
differentiation promotes BLT GVHD.
Previously in a murine model of sclerodermatous GVHD, we
identified a dermal CD11b+, MHC class II+ macrophage
population that collaborates with infiltrating CD4+ T cells to
produce pathology similar to that observed in the BLT mice with
GVHD. In sclerodermatous GVHD this population of macro-
phages expressed a mixture of markers associated with M1 or
‘‘classical’’ (Cox2, Nos2) and M2 or ‘‘alternative’’ (Ym1) macro-
phage polarization [18]. A similar dermal CD11b+, MHC class
II+ macrophage population was identified in the skin of BLT
GVHD mice (Figure 4A), which also displayed a mixed M1/M2
macrophage polarization phenotype with increased expression of
Cox2, Nos2, Arg1 and Ym1 (Figure 4B and Information S1). IL-25
has been suggested to function as a growth factor for a
macrophage-like cell population that secretes pro-fibrogenic
cytokines such as IL-13 [19,20]. Macrophages in the skin of
BLT GVHD mice displayed an upregualtion of IL25 (Figure 4B).
Additionally, these cells also express IL13Ra1 (Figure 4B), which is
upregulated in GVHD, suggesting both that they are competent to
respond to IL13, and as mentioned above, increased IL13Ra1 was
associated with an IL13-driven expression signature in murine
GVHD and human scleroderma [8]. Despite the BLT model
demonstrating robust reconstitution of human myeloid cells in the
peripheral blood, secondary lymphoid organs, vaginal mucosa and
GI tract, this macrophage population identified in the skin is
entirely mouse in origin, based on the species specificity of the
FACS and realtime PCR reagents used [21,22].
Discussion
Mice bearing a humanized immune system offer the flexibility
to experimentally manipulate human cells in vivo and a non-
primate host to model infectious agents such as HIV. Advances in
the development of humanized mice, such as co-transplantation of
human thymic and fetal liver tissue, have resulted in improved T
cell engraftment and function [1,6,7]. However, here we report
that a significant proportion of humanized mice develop clinical
GVHD, with all animals demonstrating some degree of histo-
pathologic disease. This untoward effect of reconstitution of
immunodeficient mice with a human immune system is a major
hurdle in the development of these models. Notably, other
investigators have independently observed GVHD in humanized
mice, indicating that this is a generalized phenomenon not likely to
be attributable to the specific conditions used in this study [23].
With anticipated advances in reconstituting human T cell function
in mice, we predict this issue will become progressively more
severe. The insight we provide here into the potential pathogenic
mechanisms at work will provide the basis for rational modifica-
tion of these systems to reduce this limiting complication.
Previously we observed in a fully murine model of GVHD that
the induction of a mixed M1/M2 phenotype in dermal
macrophages is associated with fibrotic skin disease [8]. A similar
phenotype has been observed with tumor-associated macrophages
[24]. Interestingly, this observation is recapitulated in the BLT
GVHD model, despite these mice displaying a significantly more
pronounced Th1 polarization than observed in the purely murine
sclerodermatous GVHD model. This suggests that factors outside
of T-cell derived Th1/Th2/Th17-associated cytokines drive the
acquisition of this phenotype. While traditional models of
fibroinflammatory disease proposed that Th2 polarization pro-
motes, and Th1 polarization inhibits, fibroinflammatory diseases,
the Th1 predominance of this model support the more textured
emerging view that, in collaboration with other factors, IFNc can
contribute to the development of fibroinflammatory diseases
[25,26,27,28,29,30]. Given that IFNc appears to have a direct
anti-fibrotic effect in several different systems, perhaps its role is
more related to mediating key inflammatory and loss of tolerance
steps in the process of disease development as opposed to being a
direct driver of fibrosis [31,32]. This is supported by the
observation that human IFNc does not cross react with murine
cells. Thus, if IFNc plays a functional role, it must be limited to its
actions on human graft-derived cells [33]. Alternatively, it is
possible that a Th1-derived factor other than IFNc is the key
cytokine in promoting GVHD in BLT mice. The difficulty in
associating fibroinflammatory diseases purely with Th1 or Th2
differentiation may also be explained by the observation that the
most potent Th2-associated pro-fibrotic cytokine, IL13, is
additionally produced by innate immune cells and production by
these sources may not be tied to Th1/Th2 skewing [24,34].
Supporting this is our observation that expression of IL13 target
gene Sprr2a is increased despite undetectable levels Th2 differen-
tiation in T cells from BLT GVHD mice [8].
The strong association between the presence of human CD4+ T
cells in the skin and GVHD suggests an obvious and direct model
for their involvement in disease. Conversely, the association of
donor HLA class I alleles with risk for GVHD suggests that CD8+
T cells also contribute. However, the absence of significant
numbers of CD8+ T cells in lesional skin makes their mode of
action less clear. One possibility is that CD8+ T cells are only
present in the skin during early subclinical disease. A second
possibility is that CD8+ T cells are involved in loss of tolerance
within secondary lymphoid organs, functioning as an early source
of IFNc that promotes Th1 skewing of CD4+ T cells. The effects
of donor HLA class I may also reflect the contribution of a class I-
dependent NK cell mechanism [35,36]. While many studies of the
influence of specific donor HLA class I alleles were conducted on
GVHD in BLT Humanized Mice
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p=.0001 by a two-tailed Student’s t-test. (B) Realtime PCR analysis for the indicated genes on RNA samples isolated from the skin of control and BLT
GVHD mice. ‘‘**’’ indicates that the signal for both HPRT and the gene of interest were below the limit of detection. (C) Realtime PCR analysis for the
indicated genes on RNA samples isolated from the skin of control and BLT GVHD mice. For all genes displayed, p,.05 by a two-tailed Student’s t-test.
(C) Flow cytometric analysis of cells isolated from the skin of BLT GVHD and control mice and stained for the indicated markers. (D) ELISA for the
indicated cytokines on tissue culture supernatants of CD4+ T cells sorted from control and BLT GVHD skin as in (C) and restimulated with PMA and
ionomycin. For IFNc,P ,.0001, for IL17, P=.0027, both by a two-tailed Student’s t-test. (E) IFNc ELISA on the tissue culture supernatants of CD4+ T
cells isolated from the spleen of control and BLT GVHD mice by magnetic bead sorting and restimulated with PMA + ionomycin. Comparing
stimulated healthy and GVHD T cells, P=.0016 by a two-tailed Student’s t-test.
doi:10.1371/journal.pone.0044664.g003
GVHD in BLT Humanized Mice
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donor HLA C401 has been identified as promoting severe GVHD
in both humans and the BLT GVHD model, suggesting that the
BLT GVHD model may be predictive of specific genetic or
environmental factors that contribute to the development of
human GVHD [11]. From a practical perspective, knowledge of
the relative risk conferred by various donor HLA class I alleles
may facilitate pre-screening of donor tissue for those that induce a
reduced burden of GVHD.
At the same time that GVHD poses a challenge for the use of
humanized mice, it presents an opportunity to study GVHD or
autoimmune-like pathology using human cells in vivo. In this
respect, BLT GVHD mice will prove useful for preclinical studies
of novel anti-inflammatory and immunosuppressive therapeutics,
providing an important point of validation that a candidate
therapeutic has activity against human cells in a complex in vivo
environment. Notably, previous models of xenogenic GVHD have
previously been reported [37,38,39,40]. These involved transfer of
human peripheral blood mononuclear cells (PBMCs) into suble-
thally irriadiated NS or NSG hosts, resulting in rapid (usually
,2 weeks) and highly penetrant disease. We propose that PBMC
models and the BLT GVH model are complimentary approaches,
with the PBMC transfer model representing acute GVHD from
the transfer of preformed effector T cells and the BLT GVH
model more accurately representing chronic GVHD, developing
over 3–4 months, arising from T cells generated de novo in the
murine host, reflecting the contribution of multiple cell types and a
multifactorial process leading to the eventual loss of host tolerance.
Notably, it has been described that human T cells in similar
models lacking a human thymic implant are able to home to the
murine thymus to generate polyclonal TCRab repertoires [41].
Thus, it is likely that T cell compartments in the BLT mice reflect
a mixture of cells educated in the human and murine thymus. It
will be of particular interest to determine the relative pathogenic
potential of each of these pools of lymphocytes.
Figure 4. Characterization of a murine macrophage population in the skin of BLT GVHD mice. (A) Representative FACS plots showing the
presence of a murine dermal macrophage population defined as CD11b
+, MHC class II
+. (B) Realtime PCR analysis for the expression of the indicated
transcripts in macrophages sorted as in (A) from control and BLT GVHD mice.
doi:10.1371/journal.pone.0044664.g004
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PLOS ONE | www.plosone.org 7 September 2012 | Volume 7 | Issue 9 | e44664In addition to the relevance of this model to human GVHD, it
partially recapitulates pathologic features of human scleroderma,
particularly with regards to the skin disease. Having a platform for
preclinical validation in a humanized system is of particular
importance for fibroinflammatory diseases such as scleroderma, as
multiple initially promising therapeutic approaches ultimately
yielded disappointing results when transitioned from preclinical
models to patients [42,43]. For future such efforts, the BLT
GVHD model could serve as a final point of preclinical evaluation
and optimization of a therapeutic before committing to human
studies. Lastly, the BLT GVHD model may be of use in addressing
clinically important questions that may be difficult to directly
address in patients, such as the effect of HIV at various stages of
infection on the incidence and severity of GVHD after allogenic
hematopoietic stem cell transplantation [44,45]. Thus, the BLT
GVHD model can also facilitate the experimental study of
questions not previously possible, such as the influence of HIV or
other pathogens studied in humanized mice on GVHD.
Supporting Information
Information S1 Table 1, Figures 1–3. Table 1: P values and
relative risk for the influence of HLA class I alleles on GVH
incidence. Relative risk and significance for various HLA class I
alleles was calculated in Figure 2. Displayed are the relative risk
values, 95% confidence intervals, and P values for each HLA
allele. Figure 1. Further histologic characterization of GVH
occurring in humanized BLT mice. (A–D)Tissues from humanized
BLT mice with clinical GVH as in Figure 1 were harvested for
histologic analysis. Figure 2. Cellular and molecular characteriza-
tion of GVH in BLT mice. Splenocytes were isolated and
stimulated as in Figure 3E, and the resulting supernatant was
analyzed for levels of IL10. Figure 3: Replicate Data for Dermal
Macrophage Expression Profile. Macrophages were isolated as in
Figure 4, RNA extracted, and expression of the indicated genes
measured by realtime PCR. Shown are independent experimental
replicates of the data provided in Figure 4B.
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